Latest Press Releases

Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases

PR Newswire SAN FRANCISCO, Jan. 10, 2025 Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated diseases Company launches with a ...

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

PR Newswire SHANGHAI, Jan. 10, 2025 SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

A Step Ahead in Paediatric Care: Manipal Hospital Whitefield Launches Dedicated Paediatric Emergency Bay

PR Newswire BENGALURU, India, Jan. 10, 2025 BENGALURU, India, Jan. 10, 2025 /PRNewswire/ -- Manipal Hospital Whitefield launched a dedicated Paediatric Emergency Bay on Wednesday, 8th Jan 2025 within its emergency department, aiming to ...

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors

PR Newswire BOSTON, Jan. 9, 2025 BOSTON, Jan. 9, 2025 /PRNewswire/ -- Servier today announced updates to two of its Phase 3 programs evaluating TIBSOVO (ivosidenib tablets) in isocitrate dehydrogenase 1 (IDH1)-mutated cancers. The first ...

SynCardia Systems Receives Decision to Grant First Patent in China for the Emperor Next-Generation Total Artificial Heart

PR Newswire TUCSON, Ariz., Jan. 9, 2025 TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ -- SynCardia Systems, LLC ("SynCardia", or the "Company"), a Picard Medical, Inc. company, and the global leader in total artificial heart technology, is ...

Crunch Fitness to Open Doors to those Affected by the Los Angeles Wildfires

PR Newswire LOS ANGELES, Jan. 9, 2025 Gyms are open to the community to charge phones, use wifi and take showers LOS ANGELES, Jan. 9, 2025 /PRNewswire/ -- With the wildfires continuing to devastate Los Angeles, Crunch Fitness is ...

Nonprofit CEOs Took the Stage at CES 2025 to Shine Spotlight on How They Use AI and Tech to Treat and Cure Critical Diseases

PR Newswire LAS VEGAS, Jan. 9, 2025 Moore CEO Gretchen Littlefield hosted a Great Minds panel on how big data and tech are being leveraged to progress treatments and cures for cancer, heart disease, Alzheimer's disease and cleft lip and ...

Premature Ejaculation Treatment Market size to increase by USD 1.53 Billion between 2024 to 2029, Market Segmentation by Route Of Administration, Drug Class, Geography , Technavio

PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The global premature ejaculation treatment market size is estimated to grow by USD 1.53 billion from 2025 to 2029, according to Technavio. The market is estimated to ...

BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis

PR Newswire LEXINGTON, Mass., Jan. 9, 2025 LEXINGTON, Mass., Jan. 9, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the ...

American Injectables Earns FDA Approval

PR Newswire BROOKSVILLE, Fla., Jan. 9, 2025 BROOKSVILLE, Fla., Jan. 9, 2025 /PRNewswire/ -- American Injectables, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, is proud to announce it has ...

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

PR Newswire CAMBRIDGE, United Kingdom and MONTREAL, Jan. 9, 2025 CAMBRIDGE, United Kingdom and MONTREAL, Jan. 9, 2025 /PRNewswire/ -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research ...

Sen-Jam Pharmaceutical Files Groundbreaking Patent for Novel Therapeutic Approach to Address Obesity and Metabolic Disorders

PR Newswire HUNTINGTON, N.Y., Jan. 9, 2025 HUNTINGTON, N.Y., Jan. 9, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a leader in innovative anti-inflammatory care, today announced the submission of a new patent application that introduces a ...

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

PR Newswire SPRING HOUSE, Pa., Jan. 9, 2025 Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody ...

Hispanic Federation and HabitNu Partner to Combat Rising Rates of Type 2 Diabetes in Hispanic Communities

PR Newswire CHICAGO, Jan. 9, 2025 CHICAGO, Jan. 9, 2025 /PRNewswire/ -- Hispanic Federation, a national nonprofit dedicated to empowering Latino communities, is partnering with HabitNu to bring the CDC-recognized Diabetes Prevention Program ...

Onkos Surgical® Successfully Completes Groundbreaking, First-in-Human Cases Using NanoCept™ Antibacterial Technology

PR Newswire PARSIPPANY, N.J., Jan. 9, 2025 PARSIPPANY, N.J., Jan. 9, 2025 /PRNewswire/ -- Onkos Surgical, a leading provider of innovative solutions for complex orthopaedic procedures, today announced that its revolutionary NanoCept ...

Astellas Receives Health Canada Approval for VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Canada NewsWire MARKHAM, ON, Jan. 9, 2025 MARKHAM, ON, Jan. 9, 2025 /CNW/ - Today, Astellas Pharma Canada Inc. is proud to announce that Health Canada has approved VYLOY® (zolbetuximab for injection), which is indicated to be used in ...

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure® Suppository Applicator for the Treatment of Ulcerative Colitis of the Rectum

PR Newswire CONCORD, Mass., Jan. 9, 2025 Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 ...

Peerbridge Health Unveils COR-INSIGHT Trial to Validate Revolutionary AI-Enabled Cardiac and Cardiopulmonary Diagnostics & Monitoring

PR Newswire BRENTWOOD, Tenn., Jan. 9, 2025 Inexpensive wearable technology for diagnostics and monitoring has the power to transform cardiac care BRENTWOOD, Tenn., Jan. 9, 2025 /PRNewswire/ -- Peerbridge Health has announced the launch ...

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

PR Newswire AURORA, Colo., Jan. 9, 2025 Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis (RA), as a ...

EDCare Introduces Residential Eating Disorder Program in Denver

PR Newswire DENVER, Jan. 9, 2025 Innovative program offers 24/7 medically supervised care in a supportive, real-world recovery setting DENVER, Jan. 9, 2025 /PRNewswire/ -- EDCare, a leading provider in the diagnosis and treatment of ...

New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer

PR Newswire FRANKLIN LAKES, N.J., Jan. 9, 2025 Women Are Seeking More Convenience and Less Discomfort in Testing Options FRANKLIN LAKES, N.J., Jan. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global ...

Resume Now Study Finds 65% of Workers Feel Empowered to Decline Extra Work

PR Newswire GUAYNABO, Puerto Rico, Jan. 9, 2025 Survey reveals 42% of employees feel relieved when they decline extra work, yet burnout and mental health struggles persist—especially among younger workers and women. GUAYNABO, Puerto ...

Ventris Medical Receives 510(k) Clearance for Innovative Backpack® Bone Graft Containment System

PR Newswire NEWPORT BEACH, Calif., Jan. 9, 2025 NEWPORT BEACH, Calif., Jan. 9, 2025 /PRNewswire/ -- Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the United States Food and Drug ...

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

PR Newswire CAMBRIDGE, England, Jan. 9, 2025 Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 ...

Recognizing Gum Disease Early: Clearwater Periodontist Explains Why It Matters

PR Newswire CLEARWATER, Fla., Jan. 9, 2025 Gum disease, also known as periodontal disease, is a silent but significant threat to oral and overall health. Britten Periodontics and Implant Dentistry is raising awareness about the importance of ...

Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

PR Newswire TUCSON, Ariz., Jan. 9, 2025 TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its whole slide imaging system, Roche Digital Pathology Dx, has received an additional 510(k) ...

Unbranded for a Fresh Start Brings Light to National Human Trafficking Awareness Month

PR Newswire SAN DIEGO, Jan. 8, 2025 SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- January marks Human Trafficking Awareness Month, a time to reflect on the millions of individuals affected by modern-day slavery and to recognize the ongoing work ...

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

PR Newswire TOKYO, Jan. 8, 2025 TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) accepted the revised supplemental ...

Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight

PR Newswire LAS VEGAS, Jan. 8, 2025 According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024–2034), owing to the rise in the launch of emerging therapies and ...

Testosterone Replacement Therapy Market to Grow by USD 461 Million (2025-2029), Driven by Awareness Initiatives on Hypogonadism and AI-Driven Market Transformation - Technavio

PR Newswire NEW YORK, Jan. 8, 2025 NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global testosterone replacement therapy market size is estimated to grow by USD 461 million from 2025-2029, according ...

Latest Press Releases

Press Releases »

Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

A Step Ahead in Paediatric Care: Manipal Hospital Whitefield Launches Dedicated Paediatric Emergency Bay

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors

SynCardia Systems Receives Decision to Grant First Patent in China for the Emperor Next-Generation Total Artificial Heart

Crunch Fitness to Open Doors to those Affected by the Los Angeles Wildfires

Nonprofit CEOs Took the Stage at CES 2025 to Shine Spotlight on How They Use AI and Tech to Treat and Cure Critical Diseases

Premature Ejaculation Treatment Market size to increase by USD 1.53 Billion between 2024 to 2029, Market Segmentation by Route Of Administration, Drug Class, Geography , Technavio

BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis

American Injectables Earns FDA Approval

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

Sen-Jam Pharmaceutical Files Groundbreaking Patent for Novel Therapeutic Approach to Address Obesity and Metabolic Disorders

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Hispanic Federation and HabitNu Partner to Combat Rising Rates of Type 2 Diabetes in Hispanic Communities

Onkos Surgical® Successfully Completes Groundbreaking, First-in-Human Cases Using NanoCept™ Antibacterial Technology

Astellas Receives Health Canada Approval for VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure® Suppository Applicator for the Treatment of Ulcerative Colitis of the Rectum

Peerbridge Health Unveils COR-INSIGHT Trial to Validate Revolutionary AI-Enabled Cardiac and Cardiopulmonary Diagnostics & Monitoring

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

EDCare Introduces Residential Eating Disorder Program in Denver

New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer

Resume Now Study Finds 65% of Workers Feel Empowered to Decline Extra Work

Ventris Medical Receives 510(k) Clearance for Innovative Backpack® Bone Graft Containment System

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

Recognizing Gum Disease Early: Clearwater Periodontist Explains Why It Matters

Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

Unbranded for a Fresh Start Brings Light to National Human Trafficking Awareness Month

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight

Testosterone Replacement Therapy Market to Grow by USD 461 Million (2025-2029), Driven by Awareness Initiatives on Hypogonadism and AI-Driven Market Transformation - Technavio

Medindia Newsletters